Mouse IgG3 binding to macrophage-like cells is prevented by deglycosylation of the antibody or by Accutase treatment of the cells.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 05 2021
13 05 2021
Historique:
received:
28
05
2020
accepted:
29
04
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
9
11
2021
Statut:
epublish
Résumé
The binding of mouse IgG3 to Fcγ receptors (FcγR) and the existence of a mouse IgG3-specific receptor have been discussed for 40 years. Recently, integrin beta-1 (ITGB1) was proposed to be a part of an IgG3 receptor involved in the phagocytosis of IgG3-coated pathogens. We investigated the interaction of mouse IgG3 with macrophage-like J774A.1 and P388D1 cells. The existence of an IgG3-specific receptor was verified using flow cytometry and a rosetting assay, in which erythrocytes clustered around the macrophage-like cells coated with an erythrocyte-specific IgG3. Our findings confirmed that receptors binding antigen-free IgG3 are present on J774A.1 and P388D1 cells. We demonstrated for the first time that the removal of N-glycans from IgG3 completely abolished its binding to the cells. Moreover, we discovered that the cells treated with Accutase did not bind IgG3, indicating that IgG3-specific receptors are substrates of this enzyme. The results of antibody-mediated blocking of putative IgG3 receptors suggested that apart from previously proposed ITGB1, FcγRII, FcγRIII, also additional, still unknown, receptor is involved in IgG3 binding. These findings indicate that there is a complex network of glycan-dependent interactions between mouse IgG3 and the surface of effector immune cells.
Identifiants
pubmed: 33986441
doi: 10.1038/s41598-021-89705-3
pii: 10.1038/s41598-021-89705-3
pmc: PMC8119965
doi:
Substances chimiques
Immunoglobulin G
0
accutase
0
Peptide Hydrolases
EC 3.4.-
Collagenases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10295Références
Immunol Rev. 2015 Nov;268(1):25-51
pubmed: 26497511
J Immunol. 2019 May 1;202(9):2782-2794
pubmed: 30894426
Cell. 2016 Jan 14;164(1-2):128-140
pubmed: 26771488
Blood. 2007 Apr 1;109(7):3099-107
pubmed: 17119123
J Immunol. 2010 Jan 1;184(1):336-43
pubmed: 19949107
J Immunol. 1999 Jun 15;162(12):7285-93
pubmed: 10358177
Cell Death Dis. 2016 Feb 18;7:e2103
pubmed: 26890142
Science. 2005 Dec 2;310(5753):1510-2
pubmed: 16322460
J Immunol. 1998 Jan 1;160(1):20-3
pubmed: 9551950
Scand J Immunol. 2004 Jan;59(1):34-9
pubmed: 14723619
J Immunol. 1996 Feb 1;156(3):1235-46
pubmed: 8558003
J Immunol. 1989 Jul 15;143(2):526-32
pubmed: 2738401
Nat Methods. 2006 Apr;3(4):287-93
pubmed: 16554834
Immunol Res. 2002;25(3):219-27
pubmed: 12018461
J Pharmacol Exp Ther. 2003 Jun;305(3):1150-62
pubmed: 12626659
Int Immunol. 1995 May;7(5):835-42
pubmed: 7547709
J Immunol Methods. 2018 Apr;455:10-13
pubmed: 29395164
Cell Adh Migr. 2012 Jan-Feb;6(1):20-9
pubmed: 22647937
J Biol Chem. 2005 May 6;280(18):18025-32
pubmed: 15741160
J Biol Chem. 1998 Mar 20;273(12):6670-8
pubmed: 9506964
Immunity. 2005 Jul;23(1):41-51
pubmed: 16039578
J Immunol. 2014 Jan 15;192(2):741-51
pubmed: 24337742
J Immunol. 1987 Jan 1;138(1):285-92
pubmed: 2431057
Sci Rep. 2016 Aug 03;6:30938
pubmed: 27484487
Inflamm Res. 2010 Aug;59(8):647-57
pubmed: 20213330
J Exp Med. 1981 Mar 1;153(3):514-9
pubmed: 7252406
Front Immunol. 2018 May 23;9:1096
pubmed: 29875771
PLoS Pathog. 2013;9(4):e1003306
pubmed: 23637599
Curr Top Microbiol Immunol. 2014;382:165-99
pubmed: 25116100
J Immunol. 2000 May 15;164(10):5313-8
pubmed: 10799893